Inozyme Pharma (INZY) investor relations material

Executive summary

• Advanced clinical trials of INZ-701 for ENPP1 Deficiency, with strategic focus on this indication and postponement of other programs.

• ENERGY 3 trial interim data show INZ-701 increases serum phosphate and maintains a favorable safety and immunogenicity profile in pediatric ENPP1 Deficiency patients, with no dropouts or dose adjustments and no new safety signals.

• Announced key regulatory milestones, including FDA and EMA designations, new ICD-10 codes for ENPP1 Deficiency, and regulatory alignment in Japan.

• Completed enrollment in the pivotal ENERGY 3 trial for pediatric ENPP1 Deficiency; topline data expected Q1 2026.

• Appointed Petra Duda, M.D., Ph.D. as Chief Medical Officer, succeeding Kurt Gunter, M.D., and implemented a 25% workforce reduction to align resources.

Financial highlights

• Net loss of $28.0 million ($0.44 per share) for Q1 2025, compared to $23.3 million ($0.38 per share) in Q1 2024.

• Operating expenses rose to $27.7 million, driven by higher R&D and restructuring charges.

• Cash, cash equivalents, and short-term investments totaled $84.8 million as of March 31, 2025, expected to fund operations into Q1 2026.

• R&D expenses were $20.4 million in Q1 2025, up $1.3 million year-over-year, mainly due to increased INZ-701 CMC costs.

• Restructuring charges of $1.9 million reflect a 25% workforce reduction.

Outlook and guidance

• Current cash and investments expected to fund operations into Q1 2026, but not for the next 12 months from filing date, raising substantial doubt about going concern.

• Additional capital will be required to continue operations and support clinical and commercialization activities.

• Expenses expected to decrease in 2025 due to program reprioritization, but will rise significantly if INZ-701 is approved and commercialized.

• ENERGY 3 topline data anticipated in Q1 2026; regulatory filings planned in the U.S., EU, and Japan.